TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET: GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET: DBMR MARKET POSITION GRID
2.8 DBMR VENDOR SHARE ANALYSIS
2.9 MULTIVARIATE MODELING
2.10 PRODUCTS LIFELINE CURVE
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.1.1 RISING R&D EXPENDITURE
3.1.2 INCREASING NUMBER OF CONTRACT RESEARCH ORGANIZATION
3.1.3 INCREASING PREVALENCE OF CHRONIC DISEASES
3.1.4 GROWTH IN THE PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES
3.2 RESTRAINTS
3.2.1 HIGH RISK RADIATION CAUSING DISEASES
3.2.2 HIGH IMPLEMENTATION COST OF IMAGING SYSTEMS
3.3 OPPORTUNITIES
3.3.1 STRATEGIC INITIATIVES FOR BUSINESS EXPANSION
3.3.2 DEVELOPMENT OF INNOVATIVE IMAGING MODALITIES AND CONTRAST AGENTS
3.3.3 EMERGING ECONOMIES
3.4 CHALLENGES
3.4.1 STRICT REGULATORY POLICIES
3.4.2 COST OF CLINICAL TRIALS
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
6 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGINGMARKET, BY PRODUCT AND SERVICES
6.1 OVERVIEW
6.2 SERVICES
6.2.1 OPERATIONAL IMAGING SERVICES
6.2.2 READ ANALYSIS SERVICES
6.2.3 TRIAL DESIGN CONSULTING SERVICES
6.2.4 SYSTEM AND TECHNICAL SUPPORT SERVICES
6.3 SOFTWARE
7 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET, BY APPLICATION
7.1 OVERVIEW
7.2 ONCOLOGY
7.2.1 ECHOCARDIOGRAPHY
7.2.2 MAGNETIC RESONANCE IMAGING
7.2.3 COMPUTED TOMOGRAPHY
7.2.4 POSITRON EMISSION TOMOGRAPHY
7.2.5 NUCLEAR MEDICINE
7.2.6 X-RAY
7.2.7 ULTRASOUND
7.2.8 OPTICAL COHERENCE TOMOGRAPHY
7.2.9 OTHERS
7.3 NEUROLOGY
7.3.1 COMPUTED TOMOGRAPHY
7.3.2 MAGNETIC RESONANCE IMAGING
7.3.3 POSITRON EMISSION TOMOGRAPHY
7.3.4 NUCLEAR MEDICINE
7.3.5 X-RAY
7.3.6 ULTRASOUND
7.3.7 OPTICAL COHERENCE TOMOGRAPHY
7.3.8 OTHERS
7.4 ENDOCRINOLOGY
7.4.1 COMPUTED TOMOGRAPHY
7.4.2 MAGNETIC RESONANCE IMAGING
7.4.3 POSITRON EMISSION TOMOGRAPHY
7.4.4 NUCLEAR MEDICINE
7.4.5 X-RAY
7.4.6 ULTRASOUND
7.4.7 OPTICAL COHERENCE TOMOGRAPHY
7.4.8 OTHERS
7.5 CARDIOLOGY
7.5.1 X-RAY
7.5.2 ULTRASOUND
7.5.3 COMPUTED TOMOGRAPHY
7.5.4 MAGNETIC RESONANCE IMAGING
7.5.5 NUCLEAR MEDICINE
7.5.6 POSITRON EMISSION TOMOGRAPHY
7.5.7 OPTICAL COHERENCE TOMOGRAPHY
7.5.8 ECHOCARDIOGRAPHY
7.5.9 OTHERS
7.6 DERMATOLOGY
7.6.1 ULTRASOUND
7.6.2 X-RAY
7.6.3 MAGNETIC RESONANCE IMAGING
7.6.4 COMPUTED TOMOGRAPHY
7.6.5 OPTICAL COHERENCE TOMOGRAPHY
7.6.6 POSITRON EMISSION TOMOGRAPHY
7.6.7 NUCLEAR MEDICINE
7.6.8 OTHERS
7.7 HEMATOLOGY
7.7.1 ULTRASOUND
7.7.2 COMPUTED TOMOGRAPHY
7.7.3 MAGNETIC RESONANCE IMAGING
7.7.4 X-RAY
7.7.5 POSITRON EMISSION TOMOGRAPHY
7.7.6 NUCLEAR MEDICINE
7.7.7 OPTICAL COHERENCE TOMOGRAPHY
7.7.8 ECHOCARDIOGRAPHY
7.7.9 OTHERS
8 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGINGMARKET, BY MODALITY
8.1 OVERVIEW
8.2 COMPUTED TOMOGRAPHY
8.3 MAGNETIC RESONANCE IMAGING
8.4 ULTRASOUND
8.5 POSITRON EMISSION TOMOGRAPHY
8.6 X-RAY
8.7 ECHOCARDIOGRAPHY
8.8 NUCLEAR MEDICINE
8.9 OPTICAL COHERENCE TOMOGRAPHY
8.10 OTHERS
9 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGINGMARKET, BY END USER
9.1 OVERVIEW
9.2 CONTRACT RESEARCH ORGANIZATION
9.3 MEDICAL DEVICE MANUFACTURERS
9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.5 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES
10 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR
10.1 OVERVIEW
10.2 DIRECT SALES
10.3 TENDERS SALES
11 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET, BY GEOGRAPHY
11.1 MIDDLE EAST AND AFRICA
11.1.1 SAUDI ARABIA
11.1.2 SOUTH AFRICA
11.1.3 REST OF MEA
11.1.3 EGYPT
11.1.4 SAUDI ARAIA
11.1.5 UNITED ARAB EMIRATES
11.1.6 ISRAEL
12 MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
13 COMPANY PROFILE
13.1 NAVITAS LIFE SCIENCES
13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 COMPANY SHARE ANALYSIS
13.1.4 SERVICE PORTFOLIO
13.1.5 RECENT DEVELOPMENTS
13.2 RESONANCE HEALTH
13.2.1 COMPANY SNAPSHOT
13.2.2 REVENUE ANALYSIS
13.2.3 COMPANY SHARE ANALYSIS
13.2.4 SERVICE PORTFOLIO
13.2.5 RECENT DEVELOPMENTS
13.3 BIOTELEMETRY, INC.
13.3.1 COMPANY SNAPSHOT
13.3.2 REVENUE ANALYSIS
13.3.3 COMPANY SHARE ANALYSIS
13.3.4 SERVICEPORTFOLIO
13.3.5 RECENT DEVELOPMENTS
13.4 IXICO PLC
13.4.1 COMPANY SNAPSHOT
13.4.2 REVENUE ANALYSIS
13.4.3 COMPANY SHARE ANALYSIS
13.4.4 SERVICE PORTFOLIO
13.4.5 RECENT DEVELOPMENTS
13.5 ICON PLC
13.5.1 COMPANY SNAPSHOT
13.5.2 REVENUE ANALYSIS
13.5.3 COMPANY SHARE ANALYSIS
13.5.4 SERVICE PORTFOLIO
13.5.5 RECENT DEVELOPMENTS
13.6 IMAGE CORE LAB
13.6.1 COMPANY SNAPSHOT
13.6.2 SERVICE PORTFOLIO
13.6.3 RECENT DEVELOPMENT
13.7 ANAGRAM 4 CLINICAL TRIALS
13.7.1 COMPANY SNAPSHOT
13.7.2 SERVICE PORTFOLIO
13.7.3 RECENT DEVELOPMENT
13.8 BIOCLINICA
13.8.1 COMPANY SNAPSHOT
13.8.2 SERVICE PORTFOLIO
13.8.3 RECENT DEVELOPMENTS
13.9 CARDIOVASCULAR IMAGING TECHNOLOGIES
13.9.1 COMPANY SNAPSHOT
13.9.2 PRODUCT PORTFOLIO
13.9.3 RECENT DEVELOPMENT
13.10 ERT CLINICAL
13.10.1 COMPANY SNAPSHOT
13.10.2 SERVICE PORTFOLIO
13.10.3 RECENT DEVELOPMENTS
13.11 INTRINSIC IMAGING
13.11.1 COMPANY SNAPSHOT
13.11.2 PRODUCT PORTFOLIO
13.11.3 SERVICE PORTFOLIO
13.11.4 RECENT DEVELOPMENTS
13.12 LYSCAUT MEDICAL IMAGING COMPANY
13.12.1 COMPANY SNAPSHOT
13.12.2 SERVICE PORTFOLIO
13.12.3 RECENT DEVELOPMENT
13.13 PAREXEL INTERNATIONAL CORPORATION
13.13.1 COMPANY SNAPSHOT
13.13.2 SERVICE PORTFOLIO
13.13.3 RECENT DEVELOPMENTS
13.14 PERSPECTUM DIAGNOSTICS
13.14.1 COMPANY SNAPSHOT
13.14.2 PRODUCT PORTFOLIO
13.14.3 SERVICE PORTFOLIO
13.14.4 RECENT DEVELOPMENTS
13.15 QUOTIENT SCIENCES
13.15.1 COMPANY SNAPSHOT
13.15.2 SERVICE PORTFOLIO
13.15.3 RECENT DEVELOPMENTS
13.16 RADIANT SAGE LLC
13.16.1 COMPANY SNAPSHOT
13.16.2 PRODUCT PORTFOLIO
13.16.3 SERVICE PORTFOLIO
13.16.4 RECENT DEVELOPMENTS
13.17 WORLDCARE CLINICAL
13.17.1 COMPANY SNAPSHOT
13.17.2 SERVICE PORTFOLIO
13.17.3 RECENT DEVELOPMENTS
14 QUESTIONNAIRE
15 RELATED REPORTS